<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01620944</url>
  </required_header>
  <id_info>
    <org_study_id>AI424-494</org_study_id>
    <secondary_id>2011-006187-47</secondary_id>
    <nct_id>NCT01620944</nct_id>
  </id_info>
  <brief_title>Open-Label Study Comparing Efficacy and Safety of ATV/RTV+3TC With ATV/RTV+TDF/FTC in HIV-Infected, Treatment Naïve Subjects, Followed by Treatment With ATV/RTV+3TC</brief_title>
  <official_title>A 48-Week, Randomized, Open-Label Phase 3B Study Comparing the Antiviral Efficacy and Safety of ATV/RTV 3TC With ATV/RTV Plus TDF/FTC In HIV-1-Infected, Treatment-Naïve Subjects, Followed By a 48-Week Period on ATV/RTV Plus 3TC</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bristol-Myers Squibb</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this study in antiretroviral (ARV)-naïve Human immunodeficiency&#xD;
      virus 1 (HIV-1) ribonucleic acid infected subjects is to compare the response rate at Week 48&#xD;
      of a daily regimen of Atazanavir (ATV)/ Ritonavir (RTV)HS 300/100 mg combined with either one&#xD;
      additional drug [Lamivudine (3TC) 300 mg daily] or 2 additional drugs&#xD;
      [Tenofovir/Emtricitabine(TDF/FTC) 300/200 mg daily].&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Business objectives have changed&#xD;
  </why_stopped>
  <start_date type="Actual">July 31, 2012</start_date>
  <completion_date type="Actual">January 22, 2013</completion_date>
  <primary_completion_date type="Actual">January 22, 2013</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of Participants With HIV-1 RNA &lt; 40 c/mL at Week 48</measure>
    <time_frame>Week 48</time_frame>
    <description>Proportion of subjects with HIV-1 RNA &lt; 40 c/mL at Week 48.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of Participants With HIV-1 RNA &lt; 400 c/mL at Week 48</measure>
    <time_frame>Week 48</time_frame>
    <description>Proportion of Participants with HIV-1 RNA &lt; 400 c/mL at Week 48.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of Participants With HIV-1 RNA &lt; 40 c/mL and &lt; 400 c/mL at Week 96</measure>
    <time_frame>Week 96</time_frame>
    <description>proportion of subjects with HIV-1 RNA &lt; 40 c/mL and &lt; 400 c/mL at Week 96.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Adverse Events Through Weeks 48 and 96</measure>
    <time_frame>through weeks 48 and 96</time_frame>
    <description>Incidence of Adverse Events through weeks 48 and 96 including serious adverse events (SAEs) and adverse events (AEs) leading to discontinuation.&#xD;
There were no SAEs or AEs reported in this early terminated study.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline in eGFR and Bone Mineral Density at Weeks 48 and 96</measure>
    <time_frame>Weeks 48 and 96</time_frame>
    <description>Percent change from baseline in eGFR and bone mineral density at weeks 48 and 96.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Newly Emergent Genotypic Substitutions and Phenotypic Resistance to Study Drugs for Virologic Failures Through Week 48 and 96</measure>
    <time_frame>Through week 48 and 96</time_frame>
    <description>Incidence of newly emergent genotypic substitutions and phenotypic resistance to study drugs for virologic failures through Week 48 and 96.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">3</enrollment>
  <condition>HIV</condition>
  <arm_group>
    <arm_group_label>Arm1: ATV/RTVHS+3TC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm2: ATV/RTVHS+TDF/FTC</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Atazanavir</intervention_name>
    <description>Capsule, oral, 300 mg, Once daily (QD), 96 weeks</description>
    <arm_group_label>Arm1: ATV/RTVHS+3TC</arm_group_label>
    <arm_group_label>Arm2: ATV/RTVHS+TDF/FTC</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ritonavir</intervention_name>
    <description>Tablets, oral, 100 mg, QD, 96 Weeks</description>
    <arm_group_label>Arm1: ATV/RTVHS+3TC</arm_group_label>
    <arm_group_label>Arm2: ATV/RTVHS+TDF/FTC</arm_group_label>
    <other_name>Ritonavir high sensitivity (RTV HS)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lamivudine</intervention_name>
    <description>Tablet, oral, 300 mg, QD, 96 Weeks</description>
    <arm_group_label>Arm1: ATV/RTVHS+3TC</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tenofovir/Emtricitabine</intervention_name>
    <description>Tablets, oral, 300/200 mg, QD, 48 Weeks</description>
    <arm_group_label>Arm2: ATV/RTVHS+TDF/FTC</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Signed Written Informed Consent&#xD;
&#xD;
               -  Freely given informed consent must be obtained from subjects prior to clinical&#xD;
                  trial participation, including informed consent for any screening procedures&#xD;
                  conducted to establish subject eligibility for the trial&#xD;
&#xD;
               -  A freely given Pharmacokinetics (PK) sub-study consent form must be obtained from&#xD;
                  the subset of subjects participating in the intensive PK sub-study&#xD;
&#xD;
          2. Target Population&#xD;
&#xD;
               -  Treatment-naive HIV-1-infected subjects (&lt; 48 hours of any ARV is allowed)&#xD;
&#xD;
               -  Subjects who have an HIV-1 Ribonucleic acid (RNA) level ≥ 1000 c/mL at screening&#xD;
&#xD;
               -  Subjects who have a Antigenic marker of helper/inducer T lymphocytes (CD4) + cell&#xD;
                  count &gt; 100 cells/mm3&#xD;
&#xD;
          3. Age and Reproductive Status&#xD;
&#xD;
               -  Men and women, 18 years of age or older (or minimum age as determined by local&#xD;
                  regulatory or legal requirements)&#xD;
&#xD;
               -  Women of childbearing potential (WOCBP) must use highly effective methods of&#xD;
                  birth control for up to 8 weeks after the last dose of investigational product to&#xD;
                  minimize the risk of pregnancy. WOCBP must follow instructions for birth control&#xD;
                  for the entire duration of the study including a minimum of 30 days after dosing&#xD;
                  has been completed&#xD;
&#xD;
        Acceptable methods of highly effective birth control include:&#xD;
&#xD;
          -  Condom with spermicide&#xD;
&#xD;
          -  Diaphragm and spermicide&#xD;
&#xD;
          -  Cervical cap and spermicide&#xD;
&#xD;
        Since acceptable and available methods of contraception vary among different countries,&#xD;
        participating women may choose their preferred contraceptive method atazanavir AI424494&#xD;
        BMS-232632 Clinical Protocol Date: 31-01-2012 33 based on physician recommendations.&#xD;
        Caution is warranted with co-administration of oral contraceptives (ethinyl estradiol and&#xD;
        norethindrone)&#xD;
&#xD;
          -  Women must have a negative serum or urine pregnancy test [minimum sensitivity 25 IU/L&#xD;
             or equivalent units of Human chorionic gonadotropin (HCG)] within 24 hours prior to&#xD;
             the start of investigational product&#xD;
&#xD;
          -  Women must not be breastfeeding&#xD;
&#xD;
          -  Sexually active fertile men must use highly effective birth control if their partners&#xD;
             are WOCBP&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Target Disease Exceptions&#xD;
&#xD;
               -  Subjects who have an HIV-1 RNA level ≥500,000 c/mL at screening&#xD;
&#xD;
               -  Screening HIV genotype showing resistance to any component of the study regimen&#xD;
                  (ATV, RTV, 3TC, TDF/FTC)&#xD;
&#xD;
               -  Previously documented HIV-2 infection&#xD;
&#xD;
          2. Medical History and Concurrent Diseases&#xD;
&#xD;
               -  Acute or chronic hepatitis B virus (HBV) or Acute hepatitis C virus (HCV)&#xD;
                  co-infection&#xD;
&#xD;
             Note - Chronic co-infection with hepatitis C is not exclusion criteria. Subjects with&#xD;
             acute hepatitis C may have the option to be screened after the event has evolved into&#xD;
             a chronic infection&#xD;
&#xD;
               -  Presence of a newly diagnosed HIV-related opportunistic infection (OI) or any&#xD;
                  medical condition requiring acute therapy at the time of enrollment. Subjects on&#xD;
                  stable maintenance therapy for an OI may be enrolled&#xD;
&#xD;
               -  Primary HIV infection&#xD;
&#xD;
               -  History or current cardiac disease, defined by presence of arrhythmias, ischemic&#xD;
                  disease, or a conduction abnormality including left bundle branch block (LBB) or&#xD;
                  left anterior fascicular block (LAFB), 2nd- or 3rd-degree atrioventricular block&#xD;
                  (AVB), or any cardiac abnormality deemed clinically significant by the&#xD;
                  investigator. In addition, the following Electrocardiogram (ECG) findings are&#xD;
                  exclusionary:&#xD;
&#xD;
                    -  PR Interval &gt; 260 msec (severe 1st degree AV Block)&#xD;
&#xD;
                    -  QRS Interval &gt; 120 msec&#xD;
&#xD;
               -  Moderate-to-severe hepatic insufficiency&#xD;
&#xD;
               -  Obstructive liver disease&#xD;
&#xD;
               -  Recent therapy with agents having significant systemic myelosuppressive,&#xD;
                  neurotoxic, pancreatotoxic, hepatotoxic or cytotoxic potential within 3 months of&#xD;
                  study start or the expected need for such therapy at the time of enrollment, or&#xD;
                  therapy with methadone or ribavirin/interferons or treatment with neurotoxic&#xD;
                  drugs or drugs that affect CYP3A4&#xD;
&#xD;
               -  Concomitant administration of a proton pump inhibitor (PPI) or H2 blocker or any&#xD;
                  other drug with potential interaction with the investigational products&#xD;
&#xD;
               -  Life expectancy &lt; 1 year according to the judgment of the investigator&#xD;
&#xD;
               -  Active alcohol or substance use sufficient, in the investigator's opinion, to&#xD;
                  prevent adequate compliance with study therapy or to increase the risk of&#xD;
                  developing pancreatitis or chemical hepatitis&#xD;
&#xD;
               -  History or ongoing psychiatry disorder&#xD;
&#xD;
               -  Any other clinical conditions or prior therapy that, in the opinion of the&#xD;
                  investigator, would make the subject unsuitable for study or unable to comply&#xD;
                  with the dosing requirements&#xD;
&#xD;
          3. Physical and Laboratory Test Findings&#xD;
&#xD;
               -  Screening laboratory analysis shows any of the following abnormal laboratory&#xD;
                  results:&#xD;
&#xD;
                    -  Grade IV glucose&#xD;
&#xD;
                    -  Grade IV electrolytes&#xD;
&#xD;
                    -  Grade IV transaminases&#xD;
&#xD;
                    -  Grade IV hematology&#xD;
&#xD;
               -  Calculated creatinine clearance &lt; 60 mL/min as estimated by the Cockcroft-Gault&#xD;
                  equation&#xD;
&#xD;
          4. Allergies and Adverse Drug Reaction&#xD;
&#xD;
               -  Hypersensitivity to any component of the study drug formulations&#xD;
&#xD;
          5. Sex and Reproductive Status&#xD;
&#xD;
               -  Pregnancy&#xD;
&#xD;
          6. Other Exclusion Criteria&#xD;
&#xD;
               -  Prisoners or subjects who are involuntarily incarcerated&#xD;
&#xD;
               -  Subjects who are compulsorily detained for treatment of either a psychiatric or&#xD;
                  physical (eg, infectious disease) illness&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bristol-Myers Squibb</last_name>
    <role>Study Director</role>
    <affiliation>Bristol-Myers Squibb</affiliation>
  </overall_official>
  <link>
    <url>http://bms.com/studyconnect/Pages/home.aspx</url>
    <description>BMS Clinical Trial Patient Recruiting</description>
  </link>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>June 13, 2012</study_first_submitted>
  <study_first_submitted_qc>June 14, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 15, 2012</study_first_posted>
  <results_first_submitted>June 3, 2021</results_first_submitted>
  <results_first_submitted_qc>July 15, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">August 6, 2021</results_first_posted>
  <last_update_submitted>July 15, 2021</last_update_submitted>
  <last_update_submitted_qc>July 15, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 6, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ritonavir</mesh_term>
    <mesh_term>Atazanavir Sulfate</mesh_term>
    <mesh_term>Tenofovir</mesh_term>
    <mesh_term>Lamivudine</mesh_term>
    <mesh_term>Emtricitabine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>3 randomized and treated</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Arm A</title>
          <description>Reference Therapy: Atazanavir, heat-stable ritonavir [ATV/RTVHS] 300/100 mg QD + Tenofovir/emtricitabine [TDF/FTC] 300/200 mg QD by mouth for 48 weeks</description>
        </group>
        <group group_id="P2">
          <title>Arm B</title>
          <description>Experimental Therapy: Atazanavir, heat-stable ritonavir [ATV/RTVHS] 300/100 mg QD + Lamivudine [3TC] 300 mg QD by mouth for 48 weeks</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Early termination of Study</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Arm A</title>
          <description>Reference Therapy: Atazanavir, heat-stable ritonavir [ATV/RTVHS] 300/100 mg QD + Tenofovir/emtricitabine [TDF/FTC] 300/200 mg QD by mouth for 48 weeks</description>
        </group>
        <group group_id="B2">
          <title>Arm B</title>
          <description>Experimental Therapy: Atazanavir, heat-stable ritonavir [ATV/RTVHS] 300/100 mg QD + Lamivudine [3TC] 300 mg QD by mouth for 48 weeks</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="2"/>
            <count group_id="B2" value="1"/>
            <count group_id="B3" value="3"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Proportion of Participants With HIV-1 RNA &lt; 40 c/mL at Week 48</title>
        <description>Proportion of subjects with HIV-1 RNA &lt; 40 c/mL at Week 48.</description>
        <time_frame>Week 48</time_frame>
        <population>Week 48 not reached for any participant, data not collected at week 48</population>
        <group_list>
          <group group_id="O1">
            <title>Arm A</title>
            <description>Reference Therapy: Atazanavir, heat-stable ritonavir [ATV/RTVHS] 300/100 mg QD + Tenofovir/emtricitabine [TDF/FTC] 300/200 mg QD by mouth for 48 weeks</description>
          </group>
          <group group_id="O2">
            <title>Arm B</title>
            <description>Experimental Therapy: Atazanavir, heat-stable ritonavir [ATV/RTVHS] 300/100 mg QD + Lamivudine [3TC] 300 mg QD by mouth for 48 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Proportion of Participants With HIV-1 RNA &lt; 40 c/mL at Week 48</title>
          <description>Proportion of subjects with HIV-1 RNA &lt; 40 c/mL at Week 48.</description>
          <population>Week 48 not reached for any participant, data not collected at week 48</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Proportion of Participants With HIV-1 RNA &lt; 400 c/mL at Week 48</title>
        <description>Proportion of Participants with HIV-1 RNA &lt; 400 c/mL at Week 48.</description>
        <time_frame>Week 48</time_frame>
        <population>Week 48 not reached for any participant, data not collected at week 48</population>
        <group_list>
          <group group_id="O1">
            <title>Arm A</title>
            <description>Reference Therapy: Atazanavir, heat-stable ritonavir [ATV/RTVHS] 300/100 mg QD + Tenofovir/emtricitabine [TDF/FTC] 300/200 mg QD by mouth for 48 weeks</description>
          </group>
          <group group_id="O2">
            <title>Arm B</title>
            <description>Experimental Therapy: Atazanavir, heat-stable ritonavir [ATV/RTVHS] 300/100 mg QD + Lamivudine [3TC] 300 mg QD by mouth for 48 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Proportion of Participants With HIV-1 RNA &lt; 400 c/mL at Week 48</title>
          <description>Proportion of Participants with HIV-1 RNA &lt; 400 c/mL at Week 48.</description>
          <population>Week 48 not reached for any participant, data not collected at week 48</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Proportion of Participants With HIV-1 RNA &lt; 40 c/mL and &lt; 400 c/mL at Week 96</title>
        <description>proportion of subjects with HIV-1 RNA &lt; 40 c/mL and &lt; 400 c/mL at Week 96.</description>
        <time_frame>Week 96</time_frame>
        <population>Week 48 not reached for any participant, data not collected at week 96</population>
        <group_list>
          <group group_id="O1">
            <title>Arm A</title>
            <description>Reference Therapy: Atazanavir, heat-stable ritonavir [ATV/RTVHS] 300/100 mg QD + Tenofovir/emtricitabine [TDF/FTC] 300/200 mg QD by mouth for 48 weeks</description>
          </group>
          <group group_id="O2">
            <title>Arm B</title>
            <description>Experimental Therapy: Atazanavir, heat-stable ritonavir [ATV/RTVHS] 300/100 mg QD + Lamivudine [3TC] 300 mg QD by mouth for 48 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Proportion of Participants With HIV-1 RNA &lt; 40 c/mL and &lt; 400 c/mL at Week 96</title>
          <description>proportion of subjects with HIV-1 RNA &lt; 40 c/mL and &lt; 400 c/mL at Week 96.</description>
          <population>Week 48 not reached for any participant, data not collected at week 96</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>HIV-1 RNA &lt; 40 c/mL</title>
            </class>
            <class>
              <title>HIV-1 RNA &lt; 400 c/mL</title>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Incidence of Adverse Events Through Weeks 48 and 96</title>
        <description>Incidence of Adverse Events through weeks 48 and 96 including serious adverse events (SAEs) and adverse events (AEs) leading to discontinuation.&#xD;
There were no SAEs or AEs reported in this early terminated study.</description>
        <time_frame>through weeks 48 and 96</time_frame>
        <population>Week 48 and 96 not reached for any participant, data not collected through week 48 and 96</population>
        <group_list>
          <group group_id="O1">
            <title>Arm A</title>
            <description>Reference Therapy: Atazanavir, heat-stable ritonavir [ATV/RTVHS] 300/100 mg QD + Tenofovir/emtricitabine [TDF/FTC] 300/200 mg QD by mouth for 48 weeks</description>
          </group>
          <group group_id="O2">
            <title>Arm B</title>
            <description>Experimental Therapy: Atazanavir, heat-stable ritonavir [ATV/RTVHS] 300/100 mg QD + Lamivudine [3TC] 300 mg QD by mouth for 48 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of Adverse Events Through Weeks 48 and 96</title>
          <description>Incidence of Adverse Events through weeks 48 and 96 including serious adverse events (SAEs) and adverse events (AEs) leading to discontinuation.&#xD;
There were no SAEs or AEs reported in this early terminated study.</description>
          <population>Week 48 and 96 not reached for any participant, data not collected through week 48 and 96</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Serious Adverse Events (SAEs)</title>
            </class>
            <class>
              <title>Adverse Events (AEs) leading to discontinuation</title>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline in eGFR and Bone Mineral Density at Weeks 48 and 96</title>
        <description>Percent change from baseline in eGFR and bone mineral density at weeks 48 and 96.</description>
        <time_frame>Weeks 48 and 96</time_frame>
        <population>Week 48 and 96 not reached for any participant, data not collected at week 48 and 96</population>
        <group_list>
          <group group_id="O1">
            <title>Arm A</title>
            <description>Reference Therapy: Atazanavir, heat-stable ritonavir [ATV/RTVHS] 300/100 mg QD + Tenofovir/emtricitabine [TDF/FTC] 300/200 mg QD by mouth for 48 weeks</description>
          </group>
          <group group_id="O2">
            <title>Arm B</title>
            <description>Experimental Therapy: Atazanavir, heat-stable ritonavir [ATV/RTVHS] 300/100 mg QD + Lamivudine [3TC] 300 mg QD by mouth for 48 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in eGFR and Bone Mineral Density at Weeks 48 and 96</title>
          <description>Percent change from baseline in eGFR and bone mineral density at weeks 48 and 96.</description>
          <population>Week 48 and 96 not reached for any participant, data not collected at week 48 and 96</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>eGFR</title>
            </class>
            <class>
              <title>Bone Mineral Density</title>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Incidence of Newly Emergent Genotypic Substitutions and Phenotypic Resistance to Study Drugs for Virologic Failures Through Week 48 and 96</title>
        <description>Incidence of newly emergent genotypic substitutions and phenotypic resistance to study drugs for virologic failures through Week 48 and 96.</description>
        <time_frame>Through week 48 and 96</time_frame>
        <population>Week 48 and 96 not reached for any participant, data not collected through week 48 and 96</population>
        <group_list>
          <group group_id="O1">
            <title>Arm A</title>
            <description>Reference Therapy: Atazanavir, heat-stable ritonavir [ATV/RTVHS] 300/100 mg QD + Tenofovir/emtricitabine [TDF/FTC] 300/200 mg QD by mouth for 48 weeks</description>
          </group>
          <group group_id="O2">
            <title>Arm B</title>
            <description>Experimental Therapy: Atazanavir, heat-stable ritonavir [ATV/RTVHS] 300/100 mg QD + Lamivudine [3TC] 300 mg QD by mouth for 48 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of Newly Emergent Genotypic Substitutions and Phenotypic Resistance to Study Drugs for Virologic Failures Through Week 48 and 96</title>
          <description>Incidence of newly emergent genotypic substitutions and phenotypic resistance to study drugs for virologic failures through Week 48 and 96.</description>
          <population>Week 48 and 96 not reached for any participant, data not collected through week 48 and 96</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Newly Emergent Genotypic Substitutions</title>
            </class>
            <class>
              <title>Phenotypic Resistance</title>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <desc>There were NO reported deaths among participants. There were NO adverse events or serious adverse events reported for any participant.</desc>
      <group_list>
        <group group_id="E1">
          <title>Arm A</title>
          <description>Reference Therapy: Atazanavir, heat-stable ritonavir [ATV/RTVHS] 300/100 mg QD + Tenofovir/emtricitabine [TDF/FTC] 300/200 mg QD by mouth for 48 weeks</description>
        </group>
        <group group_id="E2">
          <title>Arm B</title>
          <description>Experimental Therapy: Atazanavir, heat-stable ritonavir [ATV/RTVHS] 300/100 mg QD + Lamivudine [3TC] 300 mg QD by mouth for 48 weeks</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Bristol-Myers Squibb Co. agreements with investigators vary; constant is our right to embargo communications regarding trial results prior to public release for a period ≤60 days from submittal for review. We will not prohibit investigators from publishing, but will prohibit the disclosure of previously undisclosed confidential information other than study results, and request postponement of single-center publications until after disclosure of the clinical trial's primary publication.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Bristol-Myers Squibb Study Director</name_or_title>
      <organization>Bristol-Myers Squibb</organization>
      <phone>Please Email</phone>
      <email>Clinical.Trials@bms.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

